Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin

A technology of pregabalin and gabapentin, which is applied in the field of complexes of gabapentin or pregabalin and transport parts, which can solve the inconvenience to patients

Inactive Publication Date: 2007-05-23
ALZA CORP
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Practical experience with this patient inconvenience suggests that it is not the best treatment option

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
  • Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
  • Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Preparation of gabapentin-transport moiety complexes and pregabalin-transport moiety complexes

[0143] Preparation of gabapentin-transport moiety complexes

[0144] 1. Prepare a solution of 0.5 mL of 36.5% hydrochloric acid (5 mmol HCl) in 25 mL of deionized water.

[0145] 2. Add 5 mmol gabapentin (0.86 g) to the solution from step 1. The mixture was stirred at room temperature for 10 minutes. Gabapentin hydrochloride is formed.

[0146] 3. Add 5 mmol sodium lauryl sulfate (1.4 g) to the aqueous solution of step 2. The mixture was stirred at room temperature for 20 minutes.

[0147] 4. Add 50 mL of dichloromethane to the solution from step 3. The mixture was stirred at room temperature for 2 hours.

[0148] 5. Transfer the mixture from step 4 to a separatory funnel and allow it to settle for 3 hours. Two phases form, a lower phase of dichloromethane and a higher phase of water.

[0149] 6. Separate the high and low phases from step 5. The lower phase dichloro...

Embodiment 2

[0158] In Vivo Colonic Absorption in a Rat Irrigated-Ligated Colon Model

[0159] An animal model commonly known as "flush-ligated colon model" or "intracolonic ligated model" is used. Fasted 0.3-0.5 kg Sprague-Dawley male rats were anesthetized and the segment closest to the colon was isolated. Flush the fecal material from the colon. Both ends of the colon segment are ligated while a catheter is placed in the lumen and removed intraperitoneally and placed on the skin for delivery of the test formulation. The contents of the colon were rinsed and the colon was returned to the animal's abdominal cavity. According to the set experiment, the test agent was added after the segment was perfused with 1 mL / kg of 20 mM sodium phosphate buffer, pH 7.4, more accurately mimicking the actual colonic environment in the clinical setting.

[0160] Rats (n=3) were allowed to equilibrate for approximately 1 hour following surgical preparation and prior to exposure to each test fo...

Embodiment 3

[0167] Absorption in the body

[0168] 28 large rats were randomly divided into 7 test groups (n=4). The gabapentin or gabapentin-lauryl sulfate complex prepared as described in Example 1A was intubated to the beginning of the duodenum of rats at doses of 5 mg / rat, 10 mg / rat and 20 mg / large, respectively. mouse. The remaining test group received 1 mg / kg gabapentin intravenously.

[0169] Blood samples from each animal were drawn after 4 hours and analyzed for gabapentin content. The results are shown in Tables D-H and Figures 6A-6C.

[0170] Gabapentin lauryl sulfate, duodenal dose 5mg / rat

[0171] Gabapentin lauryl sulfate, duodenal dose 10mg / rat

[0172] Gabapentin lauryl sulfate, duodenal dose 20mg / rat

[0173] Gabapentin, duodenal dose 5mg / rat

[0174] Gabapentin, duodenal dose 10mg / rat

[0175] Gabapentin, duodenal dose 20mg / rat

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

A complex comprised of metformin and a transport moiety, such as a alkyl sulfate, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of the drug through a period of ten to twenty-four hours, thus enabling a once-daily dosage form for metformin.

Description

Background of the invention [0001] The present invention relates to compositions and dosage forms for the delivery of gabapentin or pregabalin. In more detail, the present invention relates to a complex of gabapentin or pregabalin and a transport moiety, wherein the complex facilitates the absorption of the drug in the gastrointestinal tract and more particularly in the lower gastrointestinal tract. Background of the invention [0002] Scientific understanding of the pathogenesis of neuropathic pain has developed over the past decade, and basic research in animal models of neuropathic pain and human clinical trials have revealed pathophysiological and biochemical changes in the nervous system due to injury or disease (Backonja, M.M., Clin. J. Pain, 16 (2): S67-72 (2000)). Neuropathic pain is a chronic condition that often occurs in cancer patients, stroke victims, the elderly, people with diabetes (eg, painful diabetic neuropathy), patients with herpes zoster (shingles) (e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/20A61K31/185A61K31/20A61P3/10C07C229/08C07C229/28
Inventor 黄锡礼晏东G·V·圭塔
Owner ALZA CORP